Intraduodenal infusion of levodopa;Infusión intraduodenal de levodopa

Revista de Neurologia

Volumn 51, Issue 1, 2010, Pages 41-48

  Valldeoriola, Francesc ^a   Cámara, Ana ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Duodopa; Intraduodenal infusion; Levodopa; Motor fluctuations; Parkinson; Percutaneous endoscopic gastrostomy

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CARBOXYMETHYLCELLULOSE;

CASE REPORT; DRUG EFFICACY; DRUG INFUSION; DUODENUM INTUBATION; DYSKINESIA; GEL; HUMAN; INFUSION SYSTEM; PARKINSON DISEASE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; REVIEW; STOMACH CONTENT; SUSPENSION;

EID: 77954421497     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5101.2010363     Document Type: Review

References (34)

1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-9.
2. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589-98.
3. Jankovic J. Levodopa strengths and weaknesses. Neurology 2002; 58 (Suppl 1): S19-32.
4. Coelho M, Martí MJ, Tolosa E, Ferreira JJ, Valldeoriola F, Rosa M, et al. Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. J Neurol 2010 [in press].
5. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1998; 24: 372-8.
6. Widnell K. Pathophysiology of motor fluctuations in Parkinson's disease. Mov Disord 2005; 20 (Suppl 11): S17-22.
7. Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci 2008; 29 (Suppl 5): S387-8.
8. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008; 23 (Suppl 3): S580-4.
9. Deleu D, Ebinger G, Michotte Y. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa. Eur J Clin Pharmacol 1991; 41: 453-8.
10. Fernández N, García JJ, Díez MJ, Sahagún AM, González A, Díez R, et al. Effects of slowed gastrointestinal motility on levodopa pharmacokinetics. Auton Neurosci 2010 [in press].
11. Meiler B, Andrich J, Müller T. Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. Mov Disord 2008; 23: 145-6.
12. Nyholm D, Jansson R, Willows T, Remahl IN. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005; 65: 1506-7.
13. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975; 25: 1144-8.
14. Chase TN, Juncos J, Serrati C, Fabrinni G, Bruno G. Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations. Adv Neurol 1987; 45: 477-80.
15. Juncos J, Serrati C, Fabrinni G, Chase TN. Fluctuating concentrations and Parkinson's disease. Lancet 1985; 2: 440.
16. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990; 27: 18-23. (Pubitemid 20031354)
17. Kurlan R, Rubin AJ, Millar C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986; 20: 262-5 (Pubitemid 16044214)
18. Bredberg E, Nilson D, Aquilonius SM, Johnels B, Nystrom C, Paalzow L. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 1993; 45: 117-22.
19. Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003; 26: 156-63.
20. Nyholm D, Nilsson-Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-23.
21. Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008; 3: 151-66.
22. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease -long-term experience. Acta Neurol Scand 2001; 104: 343-8.
23. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145-9.
24. Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008; 5: 244-6.
25. Honig H, Antonini A, Martínez-Martín P, Forgacs I, Faye GC, Fox T, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009; 24: 1468-74.
26. Puente V, De Fàbregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco R, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010; 16: 218-21.
27. Devos D; French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009; 24: 993-1000.
28. Sánchez-Castañeda C, Campdelacreu J, Miró J, Juncadella M, Jaumà S, Calopa M. Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 250-1.
29. Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008; 3: 63-73.
30. Manca D, Cossu G, Murgia D, Molari A, Ferrigno P, Marcia E, et al. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during Duodopa therapy. Mov Disord 2009; 24: 2293-4.
31. Santos-García D, Macías M, Llaneza M, Aneiros A. Suicide following duodenal levodopa infusion for Parkinson's disease. Mov Disord 2009; 24: 2029-30.
32. Santos-García D, Da Riba-Casaux M, Añón-Seijas MJ, Llaneza-González MA. Obstrucción de la sonda de infusión continua de levodopa intraduodenal resuelta mediante fluoroscopia. Rev Neurol 2010; 50: 634-5.
33. Puente-Periz V. Tratamiento con Duodopa: ventajas. Rev Neurol 2010; 50 (Supl 1): S51-3.
34. Arbelo-González JM. Tratamiento con Duodopa: inconvenientes. Rev Neurol 2010; 50 (Supl 1): S55-6.